West Pharmaceutical Services, Inc. (NYSE:WST - Get Free Report) shares traded down 3.6% during mid-day trading on Friday . The stock traded as low as $318.71 and last traded at $318.71. 154,888 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 557,395 shares. The stock had previously closed at $330.65.
West Pharmaceutical Services Price Performance
The firm has a market capitalization of $22.34 billion, a P/E ratio of 44.52, a PEG ratio of 10.21 and a beta of 1.01. The business's 50-day simple moving average is $300.36 and its 200 day simple moving average is $322.86. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its earnings results on Thursday, October 24th. The medical instruments supplier reported $1.85 EPS for the quarter, beating the consensus estimate of $1.51 by $0.34. The company had revenue of $746.90 million for the quarter, compared to analyst estimates of $709.62 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm's quarterly revenue was down .1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.16 EPS. Sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.
West Pharmaceutical Services Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 20th. Stockholders of record on Wednesday, November 13th will be issued a $0.21 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.84 annualized dividend and a dividend yield of 0.27%. This is an increase from West Pharmaceutical Services's previous quarterly dividend of $0.20. West Pharmaceutical Services's payout ratio is currently 11.38%.
Insider Activity at West Pharmaceutical Services
In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the business's stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.53% of the stock is currently owned by company insiders.
Institutional Trading of West Pharmaceutical Services
A number of institutional investors have recently modified their holdings of the company. Fidelis Capital Partners LLC purchased a new stake in West Pharmaceutical Services in the first quarter worth $27,000. Crewe Advisors LLC lifted its position in shares of West Pharmaceutical Services by 322.7% in the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier's stock worth $31,000 after purchasing an additional 71 shares during the period. Northwest Investment Counselors LLC bought a new stake in shares of West Pharmaceutical Services during the 3rd quarter valued at about $30,000. ORG Partners LLC boosted its stake in shares of West Pharmaceutical Services by 820.0% during the 1st quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier's stock valued at $55,000 after purchasing an additional 123 shares in the last quarter. Finally, Quest Partners LLC increased its position in shares of West Pharmaceutical Services by 5,633.3% during the second quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier's stock valued at $57,000 after buying an additional 169 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.
About West Pharmaceutical Services
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
